医学
神经活性类固醇
重性抑郁障碍
抗抑郁药
产后抑郁症
萧条(经济学)
精神科
经前期烦躁障碍
沃替西汀
分娩
需要治疗的数量
心理健康
怀孕
γ-氨基丁酸受体
内科学
心情
焦虑
受体
相对风险
月经周期
置信区间
宏观经济学
生物
经济
遗传学
激素
作者
S. Danielle,Nicholas Kleine,Kayla M. Teopiz,Joshua D. Di Vincenzo,Roger Ho,Stephanie L. Galibert,Amrit Samra,Samuel P.M. Zilm,H. Rebekah,Giacomo d’Andrea,Hartej Gill,Felicia Ceban,Shakila Meshkat,Sabrina Wong,Gia Han Le,Angela T.H. Kwan,Joshua D. Rosenblat,Taeho Greg Rhee,Rodrigo B. Mansur,Roger S. McIntyre
标识
DOI:10.1080/14656566.2023.2298340
摘要
Introduction Major depressive disorder (MDD) is a common and debilitating mental illness. Postpartum depression (PPD) impacts women globally and is one of the most common complications of childbirth that is underdiagnosed and undertreated, adversely impacting the mental health of women, children, and partners.Available antidepressant medications require weeks to months before showing effect. In this setting, zuranolone, an oral neuroactive steroid and a positive allosteric modulator of GABAA receptors, is an attractive alternative as a rapid-acting antidepressant treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI